Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.

Abstract:

UNLABELLED:The aminosalicylate balsalazide is a prodrug which is metabolised by bacterial azo reductases in the colon to release its therapeutically active moiety mesalazine [mesalamine (US) or 5-aminosalicylic acid] and an inert carrier molecule. The systemic absorption of balsalazide and its metabolites is not required for the therapeutic efficacy of the drug, and has been demonstrated to be limited. Data from well designed trials with a duration of 8 to 12 weeks show that oral balsalazide 6.75 g/day is as effective as (two trials) or more effective than (one trial) oral delayed-release (pH-dependent) mesalazine 2.4 g/day and appears to be as effective as oral sulfasalazine 3 g/day in the treatment of active mild-to-moderate ulcerative colitis. In addition, balsalazide appears to have a faster onset of action than mesalazine. Furthermore, balsalazide was as effective as delayed-release mesalazine (dosages used were 1.2 and 1.5 g/day, where 1.6 g/day is recommended) and oral sulfasalazine 2 g/day (recommended dosage) in the prevention of relapse in ulcerative colitis in remission after 6 to 12 months of treatment; the balsalazide dosage was 3 g/day versus mesalazine and 2 g/day versus sulfasalazine. Although not well established, additional benefits may be achieved with balsalazide dosages up to 6 g/day. Data from well designed, 2- to 12-month trials show that balsalazide is well tolerated by patients with ulcerative colitis in both acute and maintenance indications, and is better tolerated than standard formulations of sulfasalazine at therapeutically relevant dosages. CONCLUSION:Balsalazide is a well tolerated and effective first-line therapeutic option for patients with ulcerative colitis, both for the treatment of active mild-to-moderate disease and as maintenance therapy to prevent disease relapse.

journal_name

Drugs

journal_title

Drugs

authors

Muijsers RB,Goa KL

doi

10.2165/00003495-200262110-00010

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

1689-705

issue

11

eissn

0012-6667

issn

1179-1950

pii

621110

journal_volume

62

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.

    abstract::Matrix metalloproteinases (MMPs) are a family of functionally related zinc-containing enzymes that denature and degrade fibrillar collagens and other components of the extracellular matrix. Myocardial extracellular matrix remodelling and fibrosis regulated by MMPs are believed to be important contributors to the progr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161090-00002

    authors: Li YY,Feldman AM

    更新日期:2001-01-01 00:00:00

  • Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

    abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957030-00013

    authors: Prakash A,Markham A

    更新日期:1999-03-01 00:00:00

  • Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767001-00005

    authors: Arca M

    更新日期:2007-01-01 00:00:00

  • Pharmacotherapeutic management of locally advanced prostate cancer: current status.

    abstract::Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11591500-000000000-00000

    authors: Martin JM,Supiot S,Berthold DR

    更新日期:2011-05-28 00:00:00

  • Hypertension in pregnancy. Pathophysiology and management.

    abstract::Hypertension in pregnancy has implications for both maternal and fetal welfare. Extrapolation from concepts of mechanisms operating in hypertension in general to pregnancy-related hypertension is not justified. In the latter, the major features are a hyper-adrenergic state, plasma volume reduction and an increased sys...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428020-00005

    authors: Lubbe WF

    更新日期:1984-08-01 00:00:00

  • Anagrelide: a review of its use in the management of essential thrombocythaemia.

    abstract::Anagrelide (Agrylin, Xagrid) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of elevated platelet counts and t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666010-00006

    authors: Wagstaff AJ,Keating GM

    更新日期:2006-01-01 00:00:00

  • Review of cannabinoids and their antiemetic effectiveness.

    abstract::Marijuana has been used for over 2 centuries. Its major psychoactive constituent, delta-9-tetrahydrocannabinol (THC) was isolated in 1964 and first used to control nausea and vomiting during chemotherapy in the 1970s. THC has cardiovascular, pulmonary and endocrinological effects as well as actions on the central nerv...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198300251-00006

    authors: Vincent BJ,McQuiston DJ,Einhorn LH,Nagy CM,Brames MJ

    更新日期:1983-02-01 00:00:00

  • New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.

    abstract::Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare expenditure. In the United States, approximately 0.1 % of the population experiences an initial VTE event each year. Anticoagulation therapy is the cornerstone of acute VTE treatment and for prevention of recurrent VTE events. Conven...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-014-0301-x

    authors: Dobesh PP,Fanikos J

    更新日期:2014-11-01 00:00:00

  • Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

    abstract::Pegylation of interferon-alpha-2a is associated with improved sustained virological response rates in patients with chronic hepatitis C. Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterfe...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363070-00008

    authors: Keating GM,Curran MP

    更新日期:2003-01-01 00:00:00

  • Use of economic evaluation in decision making: evidence and recommendations for improvement.

    abstract::Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and pharmaceutical companies. This article illustrates the use of economic evaluation by decision makers and formulates a num...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11538120-000000000-00000

    authors: Simoens S

    更新日期:2010-10-22 00:00:00

  • Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

    abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10489100-000000000-00000

    authors: Sanford M,Scott LJ

    更新日期:2009-11-12 00:00:00

  • Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?

    abstract::During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescripti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11635860-000000000-00000

    authors: Bannwarth B

    更新日期:2012-09-10 00:00:00

  • Aliskiren/hydrochlorothiazide combination: in mild to moderate hypertension.

    abstract::Aliskiren/hydrochlorothiazide is a single-pill combination of the first in the new class of non-peptide direct renin inhibitors (aliskiren) and a thiazide diuretic (hydrochlorothiazide [HCTZ]) that achieves blood pressure (BP) reductions greater than those seen with either component alone. In double-blind, 8-week clin...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200969070-00004

    authors: Baldwin CM,Plosker GL

    更新日期:2009-01-01 00:00:00

  • A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children.

    abstract::The efficacy and tolerability of nimesulide were compared with those of paracetamol in a nonblind randomised study that recruited 110 children (64 males, 46 females; aged 3 to 6 years) with inflammation of the upper respiratory tract and fever. Nimesulide suspension (1.5 mg/kg 3 times daily) or paracetamol syrup (10 m...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300461-00059

    authors: Polidori G,Titti G,Pieragostini P,Comito A,Scaricabarozzi I

    更新日期:1993-01-01 00:00:00

  • Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products.

    abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0489-4

    authors: Trendowski M

    更新日期:2015-11-01 00:00:00

  • Optimum management of the discharging ear.

    abstract::Discharge from the ear can be the result of many disease processes. The ear may discharge blood, pus, cerebrospinal fluid (CSF) or wax. Keratosis obturans, stenosis of the external meatus and benign tumours of the external meatus all lead to wax build-up, which may cause recurrent attacks of otitis externa. Malignant ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243020-00008

    authors: Ruddy J,Bickerton RC

    更新日期:1992-02-01 00:00:00

  • Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis.

    abstract::Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01437-2

    authors: Syed YY

    更新日期:2021-01-01 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • Azimilide.

    abstract::Azimilide is a potassium channel antagonist that, in contrast to existing class III antiarrhythmic agents, blocks both the rapidly (I(Kr)) and slowly (I(Ks)) activating components of the delayed rectifier potassium current. In animal and clinical studies, azimilide prolonged repolarisation by increasing the action pot...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200059020-00016

    authors: Clemett D,Markham A

    更新日期:2000-02-01 00:00:00

  • Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?

    abstract::Follicular lymphoma (FL), the most common subtype of indolent lymphoma, is usually diagnosed at an advanced stage (III-IV), although patients are often asymptomatic. Traditionally, a palliative approach to management has been taken, cycling through watchful waiting, radiotherapy, oral alkylating agents and, eventually...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11317050-000000000-00000

    authors: Pettengell R

    更新日期:2009-01-01 00:00:00

  • Pharmacology and therapeutic use of calcitonin.

    abstract::Calcitonin is a peptide hormone secreted by the C-cells of the thyroid gland. A major physiological function of the hormone appears to be the protection of the skeleton against resorption in humans. It thus opposes the resorptive actions of parathyroid hormone and 1,25 dihydroxyvitamin D. This action is utilised pharm...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198121040-00002

    authors: Stevenson JC,Evans IM

    更新日期:1981-04-01 00:00:00

  • Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control.

    abstract:UNLABELLED:Fentanyl is a synthetic opioid agonist which interacts primarily with the mu-opioid receptor. The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for delivery by the transdermal therapeutic system. These patches are designed to deliver fentanyl at a constant rate (25, 50,...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161150-00014

    authors: Muijsers RB,Wagstaff AJ

    更新日期:2001-01-01 00:00:00

  • Controlled release metoprolol formulations. A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease.

    abstract::Conventional formulations of metoprolol have become well established in cardiovascular medicine and are particularly useful in the management of hypertension and ischaemic heart disease. Recently developed controlled release metoprolol delivery systems (metoprolol CR/ZOK and metoprolol OROS) were designed to overcome ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243030-00006

    authors: Plosker GL,Clissold SP

    更新日期:1992-03-01 00:00:00

  • Management of cystitis in young women.

    abstract::The common clinical problem of recurrent symptomatic urinary tract infections (UTI) in young women may be inconvenient and distressing to both the patient and her family, particularly if the infections are not managed in a rational manner. A suggested approach is included in table 1. ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-197713020-00003

    authors: Bailey RR

    更新日期:1977-02-01 00:00:00

  • Herb-drug interactions: a literature review.

    abstract::Herbs are often administered in combination with therapeutic drugs, raising the potential of herb-drug interactions. An extensive review of the literature identified reported herb-drug interactions with clinical significance, many of which are from case reports and limited clinical observations. Cases have been publis...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565090-00005

    authors: Hu Z,Yang X,Ho PC,Chan SY,Heng PW,Chan E,Duan W,Koh HL,Zhou S

    更新日期:2005-01-01 00:00:00

  • Lixisenatide: first global approval.

    abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0033-3

    authors: Elkinson S,Keating GM

    更新日期:2013-03-01 00:00:00

  • Treatment options for sleep apnoea.

    abstract::Sleep apnoea (SA) is a common sleep disorder affecting 4 to 25% of the adult population. The most common form, obstructive SA, is characterised by recurrent upper airway obstruction during sleep associated with sleep disruption and hypoxaemia. There is increasing evidence that SA leads to impaired vigilance, quality o...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161020-00007

    authors: Grunstein RR,Hedner J,Grote L

    更新日期:2001-01-01 00:00:00

  • Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

    abstract::During the intervening years since metoprolol was first reviewed in the Journal (1977), it has become widely used in the treatment of mild to moderate hypertension and angina pectoris. Although much data have accumulated, its precise mechanisms of action in these diseases remain largely uncertain. Optimum treatment of...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198631050-00002

    authors: Benfield P,Clissold SP,Brogden RN

    更新日期:1986-05-01 00:00:00

  • Canagliflozin: first global approval.

    abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0064-9

    authors: Elkinson S,Scott LJ

    更新日期:2013-06-01 00:00:00

  • The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

    abstract::Our knowledge of the mechanisms of platelet-mediated thrombosis has increased dramatically over the last 40 years. This increased understanding has identified treatment strategies for acute coronary syndromes (ACS) by targeting key mediators of platelet activation and aggregation processes. Aspirin (acetylsalicylic ac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11640880-000000000-00000

    authors: Angiolillo DJ

    更新日期:2012-11-12 00:00:00